CDC-RFA-CE22-2204: Expansion of Comprehensive Suicide Prevention Across the U.S.
Closed
This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control - NCIPC notices from 2022.
Centers for Disease Control - NCIPC offered grants of up to $1.0 million (at least $600,000) to any type of organization. It expected to make about 6 awards worth $26.8 million in total. Applications closed on June 6, 2022.
From the official notice on Grants.gov, last changed May 2, 2022. Checked November 7, 2026.
- Award ceiling$1.0 million
- Award floor$600,000
- Total funding$26.8 million
- Expected awards6
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | April 5, 2022 |
|---|---|
| Deadline | June 6, 2022 |
| Archived by Grants.gov | July 6, 2022 |
Who can apply
This opportunity was open to any type of organization.
All 16 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Bona fide agents are eligible to apply. For more information about bona fide agents, please see the CDC webpage on Expediting the Federal Grant Process with an Administrative Partner located at https://www.cdc.gov/publichealthgateway/grantsfunding/expediting.html#Q2 The award ceiling for this NOFO is $1,000,000. The floor is $600,000. CDC will consider any application requesting an award higher than $1,000,000 or lower than $600,000 as nonresponsive and it will receive no further review. Eligible applications must include the following to be responsive and move forward for review: A letter of commitment (LOC) from a health department officer on official letterhead supporting proposed activities. A letter of support (LOS) and prospective data use agreement (DUA) from the jurisdiction’s manager of suicide related morbidity and mortality surveillance data on official letterhead confirming data access for the applicant program. Applicants must submit the LOC, LOS & prospective DUA, name the file LOCs, LOS/ DUA and upload it as a PDF file at www.grants.gov. Applications that do not meet the above criteria will be considered non-responsive and will not move forward for review. This Notice of Funding Opportunity (NOFO) will provide an opportunity for eligible applicants not funded under CDC-RFA-CE20-2001. Organizations that are already funded under CE20- 2001 should not apply to this NOFO. This announcement will provide for the expansion of the Comprehensive Suicide Prevention Program by allowing states and other jurisdictions to participate in the program
Is this a realistic fit?
- Past Injury Prevention and Control Research and State and Community Based Programs awards averaged $2.2 million; this notice allows up to $1.0 million per award.
- Most of the program's money (76% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
CDC's Injury Center announces availability of fiscal year 2022 funds to implement CDC- RFA-CE22-2204, Expansion of Comprehensive Suicide Prevention across the United States. This funding opportunity supports implementation and evaluation of a comprehensive public health approach to suicide prevention in the U.S. This approach a) convenes and connects multi-sectoral partners (e.g., public health, mental health, people with lived experience); b) uses data to identify vulnerable populations (i.e., disproportionately affected populations [DAP]), understand contributors to suicide, and track trends in morbidity/mortality; c) assesses gaps in existing programs in the jurisdiction (d) implements complementary strategies with the best available evidence from Preventing Suicide: A Technical Package of Policy, Programs, and Practices; and e) communicates trends, progress, successes, and lessons learned to partners. The approach is rigorously evaluated with a focus on continuous quality improvement and sustained impact. The purpose is to implement and evaluate the comprehensive approach, with attention to one or more DAP, (e.g., veterans, rural communities, tribal populations, LGBTQ, homeless, other) that account for a significant proportion of the suicide burden and/or have suicide rates greater than the general population in a jurisdiction(s) (e.g., state, county, tribe). Key outcomes include a 10% reduction in suicide morbidity and mortality in the DAP(s), in the chosen jurisdiction.
Who has won Injury Prevention and Control Research and State and Community Based Programs grants before
From fiscal 2021 to 2025, Injury Prevention and Control Research and State and Community Based Programs (93.136) awarded $2.2 billion across 986 grant awards, an average of $2.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Florida Department of Health | Florida | 12 | $81.1 million |
| California Department of Public Health | California | 11 | $55.4 million |
| Ohio Department of Health | Ohio | 9 | $42.0 million |
| North Carolina Department of Health & Human Services | North Carolina | 12 | $42.0 million |
| Michigan Department of Health and Human Services | Michigan | 10 | $37.9 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-CE22-2204 still open?
No. It closed on June 6, 2022. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.
Who can apply for Expansion of Comprehensive Suicide Prevention Across the U.S.?
Centers for Disease Control - NCIPC accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Expansion of Comprehensive Suicide Prevention Across the U.S.?
Closed June 6, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $1.0 million each. About $26.8 million in total across about 6 awards.
Who has won Injury Prevention and Control Research and State and Community Based Programs grants before?
The largest recipients over five fiscal years were Florida Department of Health, California Department of Public Health, Ohio Department of Health. The program made 986 awards worth $2.2 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)